About Scipher Medicine
Scipher Medicine is a Healthcare company based in Waltham (United States) founded in 2014 by Joseph Loscalzo, Albert-Laszlo Barabasi, and Marcell Veidner. Precision medicine is delivered via liquid biopsy blood tests. Scipher Medicine has raised $232.56 million across 9 funding rounds from investors including Khosla Ventures, TD Securities and Neuberger Berman. The company has 106 employees. Scipher Medicine has completed 2 acquisitions, including CrossBridge and Yet2. Its chief executive, as recorded, is Alif Saleh. Scipher Medicine offers products and services including Spectra AI Platform, Diagnostics, and Data Lake. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its competitors include Guardant Health, GRAIL and Thrive Earlier Detection; 3 of its 3 listed competitors have raised funding.
Company details
Scipher Medicine was founded in 2014 in Waltham, United States, within the biotechnology sector. Precision medicine services are offered through a platform that analyzes blood test reports to determine suitable drugs for patients. The PrismRA test is provided to predict responses to anti-TNF therapy prior to prescription. Focus is placed on autoimmune, neurological, and cardiovascular diseases, with operations centered on liquid biopsy technologies.
- Headquarters Waltham, United States
- Employees 106
- Founders Joseph Loscalzo, Albert-Laszlo Barabasi, Marcell Veidner
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website sciphermedicine.com
- Social LinkedIn X Facebook
- Legal Name Scipher Medicine
- Total Equity Funding$232.56M (USD)
in 9 rounds
- Latest Funding Round$5.85M (USD), Series D
May 2024
- InvestorsKhosla Ventures
& 13 more
- Employee Count106
- Investments & AcquisitionsCrossBridge
& 1 more
Products & Services of Scipher Medicine
Scipher Medicine offers a comprehensive portfolio of products and services, including Spectra AI Platform, Diagnostics, and Data Lake.
Platform for analyzing patient data to optimize therapy selection.
Tools for biomarker-based therapy decisions in autoimmune diseases.
System for storing and analyzing clinical data for research insights.
Funding Insights of Scipher Medicine
Scipher Medicine has successfully raised a total of $232.56M across 9 strategic funding rounds. The most recent funding activity was a Series D round of $5.85 million completed in May 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $232.56M
- Total Rounds 9
- Last Round Series D — $5.85M
- First Round $600,000
(Dec 2015)
- Investors Count 14
All 9 funding rounds of Scipher Medicine with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2024 | $5.85M | Series D | – | – | – |
| Feb 2022 | $110M | Series D | – | Cowen | |
| Mar 2021 | $82M | Series C | – | aMoon, Northpond Ventures | |
| Feb 2020 | Series B | – | Optum Ventures | – | |
| Oct 2019 | $25M | Series B | – | Northpond Ventures | |
| Aug 2018 | $8.53M | Series A | – | Khosla Ventures | – |
| May 2018 | $795,000 | Debt – Conventional | – | – | – |
| Oct 2016 | $575,000 | Seed | – | – | – |
| Dec 2015 | $600,000 | Seed | – | – | – |
14 investors in total: 14 institutional.
Investors in Scipher Medicine
Scipher Medicine has secured backing from 14 investors, including institutional and venture fund investors. Prominent investors backing the company include Khosla Ventures, TD Securities and Neuberger Berman.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Secondary market fund focused on LP and direct secondary transactions | 1993 | nb.com | New York, United States | |
Venture capital funding is provided for technology and healthcare companies. | hitachi-ventures.com | Munich, Germany | ||
Venture capital investments in healthcare are focused on by aMoon. | amoon.fund | |||
Early-stage startups are funded by this venture capital firm. | 2004 | khoslaventures.com | Menlo Park, United States | |
Venture capital firm investing in life sciences & tech sectors | npv.vc | Cambridge, United States | ||
Early-stage tech and offline focused VC firm funding companies in the US | optumventures.com | Boston, United States | ||
Venture capital investing and portfolio management services for accredited investors. | av.vc | |||
Healthcare companies receive investments from Echo Health Ventures. | echohealthventures.com | Seattle, United States | ||
| tachyon.vc | ||||
Granpool is recognized as a venture capital investment firm. | granpool.com | Luxembourg, Luxembourg |
Investor details for Scipher Medicine
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Scipher Medicine
27 people are tracked at Scipher Medicine (14 in leadership, 1 in board & advisors, 12 in team); the tracked headcount is 106.
| Name | Role | Group |
|---|---|---|
Joseph Loscalzo | Co-Founder | Leadership |
Albert-Laszlo Barabasi | Co-Founder | Leadership |
Marcell Veidner | Co-Founder | Leadership |
Alif Saleh | CEO | Leadership |
Cali Clark | Director Billing Operations | Leadership |
Kevin Lewtas | Vice President Finance | Leadership |
Michael King | Chief Financial Officer | Leadership |
Ingo Chakravarty | Interim CEO | Leadership |
Bobby Hill | Chief Commercial Officer | Leadership |
Robert Hill | Chief Commercial Officer (CCO) | Leadership |
Kyla Pavlina | Chief People Officer | Leadership |
Sarah Rapisardo | Director, Laboratory Operations | Leadership |
Rhonda Gomez | Director Of Finance | Leadership |
Caitlin Brown | Director Of Business Development | Leadership |
Joe Loscalzo | Co-Founder | Board & advisors |
Stacey K. | Quality Contractor | Team |
Lindsay McKeown | Administrative Assistant / Office Manager | Team |
Jamiece Hargrove | Assistant Laboratory Technician | Team |
Ryan Palmer | Account Executive | Team |
Jack Bernardon | Senior Manager, Business Development | Team |
7 more people are available in the full profile.
Complete people profiles for Scipher Medicine
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Scipher Medicine
Scipher Medicine has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include CrossBridge and Yet2.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Chronic care planning and management software is provided. | crossbridge.com | Wayne, United States | 1997 | Jan 2023 | •••• | |
Management consulting, technology scouting, and licensing services are provided. | yet2.com | Waltham, United States | 1999 | Dec 2002 | $6.01M |
Complete acquisition details for Scipher Medicine
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Scipher Medicine
5 dated milestones of Scipher Medicine across 22 years, from founding to its latest funding, stage changes and deals.
- Acquisition Acquires Yet2.
- Founded Scipher Medicine is founded.
- Funding First funding round of $600K.
- Acquisition Acquires CrossBridge.
- Funding Latest funding round, Series D, of $5.8M.
Competitors of Scipher Medicine
Scipher Medicine has 3 listed competitors in our database, 3 of them funded. They include Guardant Health, GRAIL and Thrive Earlier Detection.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| guardanthealth.com | 2012 | Redwood, United States | $557.5M | 1,351 | Digital sequencing technology for cancer detection is developed. | |
| grail.com | 2016 | Menlo Park, United States | $2B | 491 | Circulating tumor DNA is screened for early cancer detection. | |
| thrivedetect.com | 2019 | Cambridge, United States | $367M | 138 | Blood-based liquid biopsy tests for multiple cancer detection are provided. |
Detailed competitors of Scipher Medicine
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Scipher Medicine
The website of Scipher Medicine (sciphermedicine.com) receives about 2.2K visits a month and ranks #4,852,187 among all websites worldwide, #5,688 in Biotechnology and Pharmaceuticals.
- Monthly visits2.2K
▼ 29% vs previous month
- Unique visitors1.3K
per month
- Global rank#4,852,187
among all websites
- Category rank#5,688
Health · Biotechnology and Pharmaceuticals
- Bounce rate38%
- Pages per visit2.2
- Average visit45 sec
- DevicesDesktop 41% · Mobile 59%
Websites whose visitors overlap most with Scipher Medicine. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| precisionmedicinegrp.com | 100% | 9.5K | #2,514,688 | View details |
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Scipher Medicine (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Scipher Medicine
Complete news archive for Scipher Medicine
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Scipher Medicine
Scipher Medicine was founded in 2014 and raised its 1st funding round 1 year after it was founded.
Scipher Medicine is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts, United States.
Alif Saleh is the CEO of Scipher Medicine, as recorded in our data.
Scipher Medicine is a funded company, having raised a total of $232.56M across 9 funding rounds to date. The company's 1st funding round was a Seed of $600K, raised on Dec 2015.
Scipher Medicine has 106 employees.
Scipher Medicine was founded in 2014 in Waltham, United States, within the biotechnology sector. Precision medicine services are offered through a platform that analyzes blood test reports to determine suitable drugs for patients. The PrismRA test is provided to predict responses to anti-TNF therapy prior to prescription. Focus is placed on autoimmune, neurological, and cardiovascular diseases, with operations centered on liquid biopsy technologies.
Scipher Medicine's top competitors include Guardant Health, GRAIL and Thrive Earlier Detection.
Scipher Medicine offers Spectra AI Platform, Diagnostics, and Data Lake.
Scipher Medicine has made 2 acquisitions, including CrossBridge, and Yet2.
Scipher Medicine has 14 investors. Key investors include Khosla Ventures, TD Securities, Neuberger Berman, Monashee Investment Management, and Hitachi Ventures.
Scipher Medicine operates through Scipher Medicine.